HDAC2 inhibitors are members of a new class of agents that modulate the expression of
genes by causing an increase in histone acetylation, thereby regulating chromatin structure …

The histone deacetylase inhibitors (HDIs) are a new class of antineoplastic agents currently
being evaluated in clinical trials. While these agents have been studied extensively in the …

Cancer is as much an epigenetic disease as it is a genetic and cytogenetic disease. The
discovery that drastic changes in DNA methylation and histone modifications are commonly …

Histone deacetylase (HDAC) inhibitors represent a new class of targeted anticancer agents.
A number of structural classes of HDAC inhibitors have been developed of which several …

Inhibitors of histone deacetylase (HDAC) are an emerging class of anticancer agents. They
induce hyperacetylation in chromatin usually resulting in activation of certain genes. They …

Purpose: The primary objectives of this trial were to define the maximum tolerated dose
(MTD) and to characterize the toxicities and pharmacokinetics of depsipeptide (FR901228) …

Histone deacetylase (HDAC) inhibitors are a new class of targeted anticancer agents.
Several HDAC inhibitors are in clinical trials and have shown significant activity against a …

Histone deacetylase (HDAC) inhibitors are emerging as an exciting new class of potential
anticancer agents for the treatment of solid and hematological malignancies. In recent years …

Histone deacetylase (HDAC) inhibitors constitute a novel and growing class of anticancer
agents that function by altering intracellular patterns of histone acetylation, the so-called …

Epigenetics as well as post-translational modifications of proteins are emerging as novel
attractive targets for anti-cancer therapy. Histone acetyltransferases (HATs) and histone …